Evidence map›Paper›PMID 40386466›Full record

ArticleBJR case reports2025

Whole-body MRI for a patient with progressive multiple myeloma.

Jonathan E Henning, Taiga Nishihori, Ciara Freeman, Alexander Lazarides, Jinming Song, Davis Kuruvilla, Sebastian Feuerlein, James R Costello

Abstract readCase Reports
In one paragraph

Article in BJR case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan E HenningUniversity of South Florida Morsani College of Medicine, Tampa, FL 33602, United States.
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.
Ciara FreemanDepartment of Blood & Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.
Alexander LazaridesDepartment of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.
Jinming SongDepartment of Hematopathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.
Davis KuruvillaUniversity of South Florida Morsani College of Medicine, Tampa, FL 33602, United States.
Sebastian FeuerleinDepartment of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.
James R CostelloDepartment of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple Myeloma represents a plasma cell disorder that can result in hallmark bony destructive change in addition to other signs of myelomatous disease. Imaging often helps in establishing the diagnosis and staging the patient. There are several different imaging modalities that can provide different levels of insight into the disease extent. We report a unique case of multiple myeloma where the progressive nature of the patient's disease highlights the strengths and limitations of the different imaging approaches. Whole-body MRI represents a noncontrast imaging technique that directly images the bone marrow space, allowing for disease detection that can precede the onset of cortical and trabecular destructive changes. In so doing, whole-body MRI provides a level of insight that far exceeds traditional plain films and even CT. Using the findings from many different imaging modalities (plain films, CT, PET-CT, and whole-body magnetic resonance imaging), we will discuss how imaging can help clinicians to better assess the patient's disease burden and complement the foundations of traditional disease monitoring (serology, histopathology from biopsy, direct clinical exam, and observation).

Indexed as

multiple myelomaprogressivewhole-body MRI

Identifiers

PMID40386466
PMCPMC12085220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.